Stocks Health care LUNG
NASDAQ · Health carePulmonx Corp (LUNG)
Pulmonx Corp brought in $87.4M of revenue over the twelve months to June 30, 2026, down 3.4% from a year earlier. It posted a net loss of $48.1M. In fiscal 2025 capital spending exceeded operating cash flow by $32.8M. At June 30, 2026 it held $55.8M in cash against $37.5M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 4, 2026.
Key facts about Pulmonx Corp
- Net worth
- Pulmonx Corp has a market value (market cap) of $120.3M at the latest share price, and shareholders' equity of $39.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $90.5M (+8.0% year on year), with a net loss of $54M. Over the 12 months to June 30, 2026: revenue $87.4M, net loss $48.1M.
- Cash flow
- In fiscal 2025 operations used $32.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 4, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Pulmonx Corp's next report was expected around October 26, 2026 and is not on file with the SEC yet.
What Pulmonx Corp does
Pulmonx Corp is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker LUNG.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $90.5M | -$54M | -$1.33 | -$32.8M |
| 2024 | $83.8M | -$56.4M | -$1.44 | -$33M |
| 2023 | $68.7M | -$60.8M | -$1.60 | -$38.4M |
| 2022 | $53.7M | -$58.9M | -$1.59 | -$46.4M |
| 2021 | $48.4M | -$48.7M | -$1.35 | -$45.1M |
| 2020 | $32.7M | -$32.2M | -$3.16 | -$31.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where LUNG ranks in Health care
Latest SEC filings
What Pulmonx Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 4.6% to $22.8M versus the same quarter last year; diluted EPS -$0.24 versus -$0.38.
- July 29, 2026
- July 29, 2026Passive stake changed SCHEDULE 13G/A
- June 4, 2026
- May 19, 2026
- May 4, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 8.7% to $20.6M versus the same quarter last year; diluted EPS -$0.33 versus -$0.36.
- April 29, 2026
- April 22, 2026
- April 22, 2026Additional proxy material DEFA14A
Insider trades
What the people running Pulmonx Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $177K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 1, 2026 | Lehman David AaronGeneral Counsel | Sold | 3,807 | $8.6K |
| September 1, 2026 | Lehman David AaronGeneral Counsel | Sold | 2,224 | $5K |
| September 1, 2026 | Lehman David AaronGeneral Counsel | Sold | 3,476 | $7.9K |
| September 1, 2026 | Lehman David AaronGeneral Counsel | Sold | 4,827 | $10.9K |
| September 1, 2026 | Rose Geoffrey BeranChief Commercial Officer | Sold | 2,213 | $5K |
| September 1, 2026 | Rose Geoffrey BeranChief Commercial Officer | Sold | 2,390 | $5.4K |
| September 1, 2026 | Rose Geoffrey BeranChief Commercial Officer | Sold | 1,530 | $3.5K |
| September 1, 2026 | Rose Geoffrey BeranChief Commercial Officer | Sold | 1,746 | $3.9K |
Who owns LUNG
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Primecap Management Co13G, passive | 12.16% | November 13, 2025 |
| Soleus Capital Master Fund, L.P.13G, passive with 5 related filers | 6.5% | March 9, 2026 |
Largest institutional holders
Insiders
11 insiders reported holding 4,370,868 shares in total, about $12.2M at the last price.
| Holder | Shares |
|---|---|
| Sung DerrickCOO and CFO | 1,335,319 |
| French Glendon E. IIIPresident and CEO, Director | 1,137,936 |
| Rose Geoffrey BeranChief Commercial Officer | 449,832 |
| Lehman David AaronGeneral Counsel | 361,827 |
| Radhakrishnan SrikanthChief Science & Techn. Officer | 316,994 |
| Mead Dana G Jr.Director | 139,714 |
| Melenikiotou GeorgiaDirector | 139,714 |
| Florin Daniel PDirector | 133,910 |
| Ferrari RichardDirector | 127,024 |
| Sullivan TiffanyDirector | 115,199 |
Questions about LUNG
What does Pulmonx Corp do?
Pulmonx Corp is a company in the Health care sector, listed on NASDAQ as LUNG. Its shares trade on NASDAQ under the ticker LUNG.
What is Pulmonx Corp's net worth?
Pulmonx Corp has a market value (market cap) of $120.3M at the latest share price, and shareholders' equity of $39.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Pulmonx Corp profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $48.1M on revenue of $87.4M.
How much revenue does Pulmonx Corp make?
Over the twelve months to June 30, 2026 Pulmonx Corp reported revenue of $87.4M. That is 3.4% less than a year earlier.
When did Pulmonx Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 4, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 3, 2026.
When is Pulmonx Corp's next earnings report?
Pulmonx Corp's next report was expected around October 26, 2026 and is not on file with the SEC yet.
Similar companies
Compare LUNG with
Follow LUNG
Get an email when Pulmonx Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Pulmonx Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.